Midas AI Signs Non-Clinical Research Agreement with Sungkyunkwan University Industry-Academic Cooperation Foundation to Verify Medical Cannabis Efficacy

[Asia Economy Reporter Hyunseok Yoo] Midas AI, which has entered the US cannabis business, is promoting medical cannabis research to expand its business domestically.

On the 4th, Midas AI signed a preclinical research contract with the Industry-Academic Cooperation Foundation of Sungkyunkwan University on "Verification of the effects of medical cannabis-based drugs on weight control and pain treatment."

The research team led by Professor Kim Dogwan of Samsung Medical Center and Sungkyunkwan University School of Medicine will verify the usefulness of cannabis in weight changes related to metabolic syndrome and chronic pain relief through preclinical studies. They plan to administer cannabis extracts orally for a certain period to observe physical changes and conduct biochemical component analysis.

Midas AI operates its cannabis business locally in the US. On the 20th of last month, it acquired shares in Melrose Facility Management (MFM), which holds a cannabis license. MFM has cannabis cultivation and extraction facilities in California.

While the legal use of cannabis is expanding in the US, its use in Korea is limited to medical purposes only. Recently, Kim Hyungdong, a member of the People Power Party (Gyeongbuk Andong·Yecheon), introduced a partial amendment bill to legally allow cannabis to be used for medical and industrial products, raising interest in cannabis utilization.

A company official stated, "Research results show that cannabidiol (CBD) extracted from cannabis can help treat brain diseases such as Alzheimer's, indicating the great potential of medical cannabis," adding, "We plan to expand our cannabis business from cultivation and extraction to local retail sales and medical research in the US."

This content was produced with the assistance of AI translation services.